We provide you with 20 years of free, institutional-grade data for CYCN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CYCN. Explore the full financial landscape of CYCN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about CYCN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Cyclerion Therapeutics, Inc(NASDAQ:CYCN) 
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator ...
Website: http://www.cyclerion.com
Founded: 2018
Full Time Employees: 94
CEO: Peter M. Hecht
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends